Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631316 | 1.00 | MEN1 (0.43) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL24631203 | 0.86 | BRD4 (0.39) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL30868590 | 0.86 | BRD4 (0.39) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL30868606 | 0.81 | SCN9A (0.41) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL24631406 | 0.81 | SCN9A (0.41) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL24631116 | 0.80 | MEN1 (0.39) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL29814319 | 0.80 | MEN1 (0.39) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL24631169 | 0.78 | MEN1 (0.41) | MEN1ALOX15MAPK1KMT2ASCN9A | |
| SCHEMBL24631283 | 0.77 | NR1I2 (0.42) | MEN1ALOX15MAPK1KMT2ABRAF | |
| SCHEMBL30868617 | 0.77 | NR1I2 (0.42) | MEN1ALOX15MAPK1KMT2ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | TEAD2, TEAD3, TEAD4 | MEN1 4234/4885ALOX15 1578/4885MAPK1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.